WSWongi Seol

Wongi Seol

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wongi Seol has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Ilhong Son

    InAm Neuroscience Research Center, Wonkwang University, Sanbon Medical Center, Sanbon-Ro, Gunpo-Si, 15865, Republic of Korea

    16 shared publications
  • Dong Hwan Ho

    InAm Neuroscience Research Center, Sanbon Medical Center, College of Medicine, Wonkwang University, 321, Sanbon-ro, Gunpo-si 15865, Republic of Korea

    10 shared publications
  • Hyejung Kim

    InAm Neuroscience Research Center, Sanbon Medical Center, College of Medicine, Wonkwang University, Gunpo 15865, Korea

    7 shared publications
  • Daleum Nam

    InAm Neuroscience Research Center, Sanbon Medical Center, College of Medicine, Wonkwang University, Gunpo 15865, Korea

    6 shared publications
  • Dong Hwan Ho

    InAm Neuroscience Research Center, Sanbon Medical Center, College of Medicine, Wonkwang University, Gyeonggido 15865, Korea

    5 shared publications
  • Hyemyung Seo

    Department of Molecular and Life Sciences, Hanyang University, Ansanshi, Gyeonggido, Republic of Korea

    4 shared publications

Latest Publications

  • Open Access

    LRRK2 Inhibition Mitigates the Neuroinflammation Caused by TLR2-Specific α-Synuclein and Alleviates Neuroinflammation-Derived Dopaminergic Neuronal Loss

    by Dong-Hwan Ho, Daleum Nam, Mikyoung Seo, Sung-Woo Park, Wongi Seol, Ilhong Son

    Evidence suggests that crosstalk occurs between microglial leucine-rich repeat kinase 2 (LRRK2)—a regulator of neuroinflammation—and neuron-released α-synuclein (αSyn)—a promoter of microglial activation and neuroinflammatory responses—in neuroinflammation-mediated Parkinson’s disease (PD) progression. Therefore, we examined whether LRRK2 inhibition reduces the responses of microglia to neuroinflammation caused by neuron-released αSyn. We examined the neuroinflammatory responses provoked by Toll-like receptor 2 (TLR2)-positive αSyn of neuronal cells using an LRRK2 inhibitor in the mouse glioma cells, rat primary microglia, and human microglia cell line; and the effects of LRRK2 inhibitor in the co-culture of ectopic αSyn-expressing human neuroblastoma cells and human microglia cells and in mouse models by injecting αSyn. We analyzed the association between LRRK2 activity and αSyn oligomer and TLR2 levels in the substantia nigra tissues of human patients with idiopathic PD (iPD). The TLR2-specific αSyn elevated LRRK2 activity and neuroinflammation, and the LRRK2 inhibitor ameliorated neuroinflammatory responses in various microglia cells, alleviated neuronal degeneration along with neuroinflammation in the co-culture, and blocked the further progression of locomotor failure and dopaminergic neuronal degeneration caused by TLR2-specific αSyn in mice. Furthermore, LRRK2 phosphorylation was increased in patients with iPD showing αSyn-specific high TLR2 level. These results suggest the application of LRRK2 inhibitors as a novel therapeutic approach against αSyn-mediated PD progression.


  • Open Access

    Ciliogenesis is Not Directly Regulated by LRRK2 Kinase Activity in Neurons

    by Hyejung Kim, Hyuna Sim, Joo-Eun Lee, Mi Kyoung Seo, Juhee Lim, Yeojin Bang, Daleum Nam, Seo-Young Lee, Sun-Ku Chung, Hyun Jin Choi, et al.

    Hyejung Kim, Hyuna Sim, Joo-Eun Lee, Mi Kyoung Seo, Juhee Lim, Yeojin Bang, Daleum Nam, Seo-Young Lee , Sun-Ku Chung, Hyun Jin Choi, Sung Woo Park, Ilhong Son, Janghwan Kim and Wongi Seol. Exp Neurobiol 2021;30:232-43. https://doi.org/10.5607/en21003


  • Open Access

    Analysis of α-synuclein levels related to LRRK2 kinase activity: from substantia nigra to urine of patients with Parkinson’s disease

    by Daleum Nam, Ami Kim, Sun Jung Han, Sung-Ik Lee, Sung-Hye Park, Wongi Seol, Ilhong Son, Dong Hwan Ho

    Research on Parkinson’s disease (PD) has been focused on the development of PD diagnostic tools as much as the development of PD therapeutics. Several genetic culprits of PD, including DJ-1, Leucine-rich repeat kinase 2 (LRRK2), and α-synuclein (α-syn), have been investigated as markers of PD in human biofluids. Unfortunately, the approaches to develop PD diagnostic tools are impractical, and there is a considerable demand for an appropriate marker of PD. The measurement of α-syn in biofluids has recently been made more accurate by examining monomers and aggregates separately using enzyme-linked immunosorbent assay (ELISA). Previously, we reported on the development of two types of sandwich ELISA for total α-syn and MJFR-14-6-4-2 antibody-specific α-syn fibrillar oligomers. The pathogenic LRRK2 G2019S mutation is related to increased α-syn secretion in the extracellular space. We tested our established ELISA using differentiated SH-SH5Y cells transfected with LRRK2 G2019S. The secretory levels of fibrillar oligomeric α-syn divided by total α-syn were significantly increased in LRRK2 G2019S-expressing cells. Additionally, substantia nigra lysates or concentrated urine from PD patients and non-PD subjects were analyzed. We observed ambiguous changes in the levels of total or fibrillar oligomeric α-syn and their ratio between PD and non-PD. Despite the insignificant increase in the relative levels of fibrillar oligomeric α-syn to total α-syn in PD, the duration of disease progression after diagnosis significantly corresponded to the relative levels of fibrillar oligomeric α-syn to total α-syn in the urine. These results might provide greater understanding for the next stage of development of α-syn ELISAs.


  • Open Access

    LRRK2 Kinase Inhibitor Rejuvenates Oxidative Stress‐Induced Cellular Senescence in Neuronal Cells

    by Dong Hwan Ho, Daleum Nam, Mi Kyoung Seo, Sung Woo Park, Wongi Seol, Ilhong Son

    Background. Leucine‐rich repeat kinase 2 (LRRK2) plays a critical role in the pathogenesis of Parkinson’s disease (PD). Aging is the most critical risk factor for the progression of PD. The correlation between aging and cellular senescence has been established. Cellular senescence is correlated with the dysregulation of the proteolytic pathway and mitochondrial dysfunction, which are also associated with the aggregation of α‐synuclein (α‐syn). Methods. Human dopaminergic neuron‐like cells (differentiated SH‐SY5Y cells) were treated with rotenone in the presence or absence of the LRRK2 kinase inhibitor GSK2578215A (GSK‐KI) for 48 h. The markers of cellular senescence, including p53, p21Waf1/Cip1 (p21), β‐galactosidase (β‐gal), Rb phosphorylation, senescence‐associated (SA) β‐gal activity, and lysosomal activity, were examined. The dSH cells and rat primary cortical neurons were treated with α‐syn fibrils 30 min before treatment with rotenone in the presence or absence of GSK‐KI for 48 h. Mice were intraperitoneally injected with rotenone and MLi‐2 (LRRK2 kinase inhibitor) once every two days for two weeks. Results. Rotenone upregulated LRRK2 phosphorylation and β‐gal levels through the activation of the p53‐p21 signaling axis and downregulated Rb phosphorylation. Additionally, rotenone upregulated SA β‐gal activity, reactive oxygen species levels, and LRRK2 phosphorylation and inhibited lysosome activity. Rotenone‐induced LRRK2 upregulation impaired the clearance of α‐syn fibrils. Treatment with LRRK2 inhibitor mitigated rotenone‐induced cellular senescence and α‐syn accumulation. Conclusions. Rotenone‐induced upregulation of LRRK2 kinase activity promoted cellular senescence, which enhanced α‐syn accumulation. However, the administration of an LRRK2 kinase inhibitor rejuvenated rotenone‐induced cellular senescence.


  • Open Access

    Urinary Biomarkers for Neurodegenerative Diseases

    by Wongi Seol, Hyejung Kim, Ilhong Son

    Wongi Seol, Hyejung Kim and Ilhong Son. Exp Neurobiol 2020;29:325-33. https://doi.org/10.5607/en20042


  • Open Access

    Leucine-rich Repeat Kinase 2 (LRRK2) Phosphorylates Rab10 in Glia and Neurons

    by Dong Hwan Ho, Daleum Nam, Mi Kyoung Seo, Sung Woo Park, Ilhong Son, Wongi Seol

    Dong Hwan Ho, Daleum Nam, Mi Kyoung Seo, Sung Woo Park, Ilhong Son and Wongi Seol. BSL 2019;25:177-84. https://doi.org/10.15616/BSL.2019.25.2.177


  • Open Access

    Rab GTPases as Physiological Substrates of LRRK2 Kinase

    by Wongi Seol, Daleum Nam, Ilhong Son

    Seol W, et al. Exp Neurobiol. 2019 Apr;28(2):134-145. https://doi.org/10.5607/en.2019.28.2.134


  • Open Access

    G2019s LRRK2 promotes mitochondrial fission and increases TNFα-mediated neuroinflammation responses

    by Dong Hwan Ho, Heajin Lee, Ilhong Son, Wongi Seol

    Leucine rich-repeat kinase 2 (LRRK2) is involved in the pathogenesis of Parkinson’s disease (PD). LRRK2 has kinase and GTPase activities, and mediates several cell functions, including vesicle trafficking, apoptosis, autophagy, mitochondrial dynamics, and neuroinflammation. G2019S (GS) is the most prevalent mutation of LRRK2. The mutation increases kinase activity, suggesting that this activity is crucial for PD pathogenesis. The activation and inhibition of LRRK2 kinase increases and reduces the levels of proinflammatory cytokines, respectively suggesting that the role of LRRK2 in neuroinflammation is critical for the pathology of PD. Previously, we demonstrated that microglial activation by lipopolysaccharide (LPS) increases mitochondrial fission via the activation of LRRK2 kinase, while LRRK2 kinase inhibition diminishes the fission morphology and release of tumor necrosis factor-alpha (TNFα) in BV2 or rat primary microglia and the brains of GS transgenic mice. In this study, the ectopic expression of GS LRRK2 in BV2 cells significantly elevated the expression of Drp1 along the fragmented mitochondria and decreased mitochondria size compared with controls. GS LRRK2-transfected BV2 cells displayed significantly increased TNFα release and neuronal death. Inhibition of LRRK2 kinase alleviated these features. TNFα levels in brains of GS mice were significantly increased compared to those in their littermates. These data further support our previous findings concerning LPS-induced neuroinflammation and mitochondrial fission in microglia via LRRK2 kinase activation.


  • Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein

    by Dong Hwan Ho, Wongi Seol, Ilhong Son

    Parkinson’s disease (PD) is characterized by the degeneration of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (LB) in neurons. α-Synuclein (αSyn) is a major component of LB and promote the PD pathogenesis via its accumulation by the impaired proteasomal or autophagic clearance. Numerous studies have revealed that the reduction of proteasome activity and autophagy is accelerated by cellular senescence. Leucine-rich repeat kinase 2 (LRRK2) contributes to PD progression and its most prevalent mutation, G2019S LRRK2, increases its activity. Our previous report has shown that the G2019S LRRK2 mutant promoted p53-induced p21 expression and neuronal cytotoxicity. The p53-p21 pathway plays a role in cellular senescence. We hypothesized that the loss of dopaminergic neurons by the stimulated p53-p21 pathway via the G2019S LRRK2 mutation might be associated with cellular senescence, thereby promoting the accumulation of αSyn. We confirmed that the ectopic expression of the phosphomimetic p53 mutant, p21, or G2019 in differentiated SH-SY5Y cells increased the following: 1) the expression of β-galactosidase, a marker of cellular senescence, and the activity of senescence-associated β-galactosidase, 2) endogenous αSyn protein level, but not its mRNA level, and 3) αSyn fibril accumulation in dSH-SY5Y via low proteasome and cathepsin D activities. Elevated oligomeric αSyn and the increase in β-galactosidase with induced p21 were observed in brain lysates of G2019S transgenic mice. Our results suggest that cellular senescence is promoted via the p53-p21 pathway due to the G2019S LRRK2 mutation. Eventually, decreased protein degradation by G2019S-mediated senescence could accelerate αSyn aggregate formation.


  • LRRK2 impairs autophagy by mediating phosphorylation of leucyl‐tRNA synthetase

    by Dong Hwan Ho, Hyejung Kim, Daleum Nam, Hyuna Sim, Janghwan Kim, Hyung Gun Kim, Ilhong Son, Wongi Seol

    Leucine‐rich repeat kinase 2 (LRRK2) is a causal gene of Parkinson disease. G2019S pathogenic mutation increases its kinase activity. LRRK2 regulates various phenotypes including autophagy, neurite outgrowth, and vesicle trafficking. Leucyl‐tRNA synthetase (LRS) attaches leucine to tRNALeu and activates mTORC1. Down‐regulation of LRS induces autophagy. We investigated the relationship between LRRK2 and LRS in regulating autophagy and observed interaction between endogenous LRRK2 and LRS proteins and LRS phosphorylation by LRRK2. Mutation studies implicated that T293 in the LRS editing domain was a putative phosphorylation site. Phospho‐Thr in LRS was increased in cells overexpressing G2019S and dopaminergic neurons differentiated from induced pluripotent stem (iPS) cells of a G2019S carrier. It was decreased by treatment with an LRRK2 kinase inhibitor (GSK2578215A). Phosphomimetic T293D displayed lower leucine bindings than wild type (WT), suggesting its defective editing function. Cellular expression of T293D increased expression of GRP78/BiP, LC3B‐II, and p62 proteins and number of LC3 puncta. Increase of GRP78 and phosphorylated LRS was diminished by treatment with GSK2578215A. Levels of LC3B, GRP78/BiP, p62, and α‐synuclein proteins were also increased in G2019S transgenic (TG) mice. These data suggest that LRRK2‐mediated LRS phosphorylation impairs autophagy by increasing protein misfolding and endoplasmic reticulum stress mediated by LRS editing defect.Significance of the study: Leucine‐rich repeat kinase 2 (LRRK2) is the most common genetic cause of Parkinson disease (PD), and the most prevalent pathogenic mutation, G2019S, increases its kinase activity. In this study, we elucidated that leucyl‐tRNA synthetase (LRS) was an LRRK2 kinase substrate and identified T293 as an LRRK2 phosphorylation site. LRRK2‐meidated LRS phosphorylation or G2019S can lead to impairment of LRS editing, increased ER stress, and accumulation of autophagy markers. These results demonstrate that LRRK2 kinase activity can facilitate accumulation of misfolded protein, suggesting that LRRK2 kinase might be a potential PD therapeutic target along with previous studies.